Q3 EPS Estimates for OTCMKTS:BIOVF Reduced by HC Wainwright

Key Points

• HC Wainwright cut its Q3 2026 EPS estimate for Swedish Orphan Biovitrum to $0.63 from $0.69, while maintaining a Buy rating on the stock.
• The firm also trimmed its outlook across later periods, projecting FY2026 EPS of $1.94 and FY2027 EPS of $3.36.
• Swedish Orphan Biovitrum most recently beat expectations in its April quarter, reporting EPS of $0.45 versus the $0.38 consensus and revenue of $755.76 million, slightly above estimates.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2026 EPS estimates for shares of Swedish Orphan Biovitrum in a report issued on Friday, July 17th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn $0.63 per share for the quarter, down from their previous forecast of $0.69. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Swedish Orphan Biovitrum's current full-year earnings is $1.94 per share. HC Wainwright also issued estimates for Swedish Orphan Biovitrum's Q4 2026 earnings at $0.60 EPS, FY2026 earnings at $1.94 EPS, Q1 2027 earnings at $0.62 EPS, Q2 2027 earnings at $0.68 EPS, Q3 2027 earnings at $1.05 EPS, Q4 2027 earnings at $1.03 EPS and FY2027 earnings at $3.36 EPS.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last released its earnings results on Tuesday, April 28th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 4.74% and a return on equity of 18.27%. The firm had revenue of $755.76 million during the quarter, compared to the consensus estimate of $749.76 million.

Several other analysts have also recently issued reports on BIOVF. Zacks Research raised shares of Swedish Orphan Biovitrum to a "hold" rating in a research note on Thursday, May 7th. Barclays reaffirmed an "overweight" rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Finally, Pareto Securities cut Swedish Orphan Biovitrum to a "hold" rating in a report on Monday, June 29th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Swedish Orphan Biovitrum currently has an average rating of "Moderate Buy".

Swedish Orphan Biovitrum Stock Performance

OTCMKTS:BIOVF opened at $49.03 on Monday. The company has a quick ratio of 0.47, a current ratio of 0.70 and a debt-to-equity ratio of 0.19. The company has a market cap of $17.45 billion, a P/E ratio of 108.95 and a beta of 0.35. Swedish Orphan Biovitrum has a fifty-two week low of $28.93 and a fifty-two week high of $49.03. The firm's 50 day moving average is $47.95 and its two-hundred day moving average is $42.20.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi's strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company's marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.